Supplementary Table S8 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

<p>Multivariate Cox regression analysis of 5-year and 8-year recurrence-free survival (RFS) for basal-like/non-basal categories variables in the GEICAM_CIBOMA translational study cohort</p>

Authors

Laura Torrecillas (ORCID: https://orcid.org/0000-0003-1302-4389)
Francisco Ayala (ORCID: https://orcid.org/0000-0001-6311-920X)
Federico Rojo (ORCID: https://orcid.org/0000-0001-9989-0290)
Begoña Bermejo (ORCID: https://orcid.org/0000-0001-7773-5994)
José Bines (ORCID: https://orcid.org/0000-0003-2465-8854)
Roberto Torres (ORCID: https://orcid.org/0000-0002-1397-4993)
Agustí Barnadas (ORCID: https://orcid.org/0000-0002-0429-1349)
José Á. García-Sáenz (ORCID: https://orcid.org/0000-0001-6880-0301)
Antonio Llombart‐Cussac (ORCID: https://orcid.org/0000-0003-4515-8293)
Lourdes Calvo (ORCID: https://orcid.org/0000-0001-8314-0241)
Raúl Rincón (ORCID: https://orcid.org/0000-0003-0576-0618)
Jesús Herránz (ORCID: https://orcid.org/0000-0002-7385-1311)
Juan de la Haba-Rodríguez (ORCID: https://orcid.org/0000-0001-5111-1702)
Ángel Guerrero‐Zotano (ORCID: https://orcid.org/0000-0003-0318-9120)
José Manuel Baena-Cañada (ORCID: https://orcid.org/0000-0002-8403-9804)
Henry Gómez (ORCID: https://orcid.org/0000-0003-2660-1843)
María Rodríguez de la Borbolla
Manuel Ruíz-Borrego (ORCID: https://orcid.org/0000-0002-1181-5622)
Rosalía Caballero (ORCID: https://orcid.org/0000-0002-6027-1748)
Sandra Pérez‐Buira (ORCID: https://orcid.org/0000-0002-2048-4503)
Miguel Martín (ORCID: https://orcid.org/0000-0001-9237-3231)
Carlos H. Barrios (ORCID: https://orcid.org/0000-0001-6021-667X)
Partha S. Ray (ORCID: https://orcid.org/0000-0002-1594-1386)
Clive R. Taylor (ORCID: https://orcid.org/0000-0002-0832-5366)

Publication Details

Published: 2025-09-02
DOI: https://doi.org/10.1158/1078-0432.30029014
Primary Topic: Advanced Breast Cancer Therapies
Type: article
Field-Weighted Citation Impact: 0.00

Supplementary Table S8 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

Laura Torrecillas, Francisco Ayala, Federico Rojo, Begoña Bermejo, José Bines, Roberto Torres, Agustí Barnadas, José Á. García-Sáenz, Antonio Llombart‐Cussac, Lourdes Calvo, Raúl Rincón, Jesús Herránz, Juan de la Haba-Rodríguez, Ángel Guerrero‐Zotano, José Manuel Baena-Cañada, Henry Gómez, María Rodríguez de la Borbolla, Manuel Ruíz-Borrego, Rosalía Caballero, Sandra Pérez‐Buira, Miguel Martín, Carlos H. Barrios, Partha S. Ray, Clive R. Taylor

September 2, 2025article en

Supplementary Table S8 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

Authors

Publication Details

Supplementary Table S8 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

Supplementary Table S8 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

Abstract

Ask Laika to Summarize, Analyze, and Connect papers live on the map.